Those interested in investing in promising biotech small-caps should keep Vidac Pharma on the radar. Despite its manageable size, the Company is already in the clinical development phase. The best-known product, VDA-1275, is the focus of interest according to a specialist article, as this drug candidate for the treatment of solid tumors has achieved impressive results in preclinical studies. As a monotherapy, VDA-1275 shows significant efficacy against tumors. Even more remarkable are the synergistic effects observed when VDA-1275 is used in combination with conventional cancer therapies.
News & Events